HOME >> MEDICINE >> NEWS
GroPep starts Phase 1 infertility trial

GroPep's program - to develop a treatment for a condition that potentially causes 50% of all miscarriages - reached a major milestone today with commencement of recruitment of healthy women volunteers into a Phase 1 trial of its infertility drug, PV903.

The drug is targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus a condition for which there is no current treatment.

The market for a drug to treat this condition is estimated to be up to US$750 million annually.

Listed biopharmaceutical company GroPep Limited (ASX:GRO) announced today that it will commence a Phase 1 trial of its infertility drug PV903. The trial, which will be conducted under the Therapeutic Goods Administration Clinical Trial Notification scheme, was approved by the Royal Adelaide Hospital Research Ethics Committee.

Recruitment will begin immediately to allow medical screening and enrolment of the first cohort of subjects in mid-February 2006. The results of the trial should be known in late 2006, depending on recruitment rate.

The trial, conducted at the CMAX Adelaide-based facilities, involves healthy female volunteers each receiving a single administration of PV903 gel (or placebo) as they are enrolled sequentially into three groups with the PV903 dose escalating between groups. A total of 36 volunteers will complete the trial. The objectives of the trial are to evaluate the safety and tolerability of vaginally administered PV903 gel, and to determine whether PV903 has effects on vaginal immune cells in a manner consistent with its proposed role in treating immunebased infertility.

Over 50% of miscarriages have no apparent explanation and some scientists believe that women who suffer from repeated miscarriage have an immune system that attacks the embryo as "foreign". PV903 is a recombinant version of a protein that is naturally found in semen and thought to be re
'"/>

Contact: Mr Tony Mitchell
61-283-547-700
Research Australia
9-Jan-2006


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep completes final milestone of the path malaria vaccine initiative
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Coffee jump-starts short-term memory
7. Epidemiology in Europe: the problem starts in childhood
8. GSK announces launch of largest ever Phase III trial in lung cancer treatment
9. Phase II study shows combination improves survival of metastatic melanoma patients
10. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
11. Drug combination proves effective against myeloma in Phase I trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/11/2019)... ... 2019 , ... Dr. John V. Prunskis, co-founder and co-Medical Director of the ... Management Best Practices Task Force (Pain Task Force) met last Monday with Joe Grogan, ... the HHS Pain Task Force’s final report that was submitted to Congress in May ...
(Date:11/9/2019)... ... November 08, 2019 , ... The Women’s Dermatologic Society (WDS) announced that Marta ... WDS Board of Directors appointed Molly Hinshaw, MD to fill the remainder of Dr. ... 2020 term and will be presented to the membership as the 2020-2021 President at ...
(Date:11/9/2019)... ... ... Mount Sinai Medical-Legal Partnership (MSMLP), an organization formed to address the legal needs ... and advocacy assistance to families and patients in need. The announcement was made at ... of Blaine (“Fin”) Fogg, who was a member of the Boards of Trustees of ...
(Date:11/7/2019)... , ... November 06, 2019 , ... Atlantic Ultraviolet Corporation ... flu is to get the flu shot. Since the flu season starts in October ... in early Fall, where their employees can simply sign-up and get their shot. , ...
(Date:11/7/2019)... ... 2019 , ... ALZYN, LLC today announced that The Silicon Review Magazine has ... “The Silicon Review 50 Best Companies to Watch 2019 program identifies companies which are ... winning a spot on this list indicates the company has distinguished itself from peers ...
Breaking Medicine News(10 mins):
(Date:11/6/2019)... ... November 06, 2019 , ... Doral Health & Wellness, ... Adult Day Care Center on Pitkin Avenue in the Brownsville section of Brooklyn. ... managing and preventing diabetes. Seniors can take part in fitness and meditation classes, ...
(Date:11/6/2019)... ... November 06, 2019 , ... On ... Westchester Hospital (NWH) President and CEO, Joel Seligman, with the Make A Difference ... commitment to raising awareness, providing education and registering lifesaving donors. Assemblyman David Buchwald, ...
(Date:11/5/2019)... Va. (PRWEB) , ... November ... ... Interactive Workshops, Wednesday-Thursday, Nov. 13-14: How to Build a Sponsor Risk Management ... Resources International, Inc., Wednesday-Friday, Nov. 13-15, 2019 • Philadelphia, PA , ...
Breaking Medicine Technology:
Cached News: